ArticleEClinicalMedicine2025
Physical morbidities in survivors of testicular germ cell tumors during childhood, adolescence, and young adulthood: a population-based retrospective matched cohort study.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While testicular germ cell tumors (TGCT) survival exceeds 90%, many survivors of adult TGCT are at risk for treatment toxicities. Less is known about physical morbidities in children, adolescents, and young adults (CAYA) with TGCT. Methods: We used the Pediatric Oncology Group of Ontario Networked Information System, the Initiative to Maximize Progress in Adolescent and Young Adult Cancer Therapy, and the Ontario Cancer Registry to identify all CAYA males diagnosed with TGCT from 1992 to 2021 at age 11-21 years in Ontario, Canada. We matched patients at TGCT diagnosis (one-to-five ratio) to cancer-free males from the general Ontario population who were identified from the Registered Person Database. We linked CAYA to health administrative databases to identify subsequent malignant neoplasms (SMN) and hearing loss/aid use after TGCT diagnosis. We assessed cardiovascular disease (CVD), dialysis, and kidney transplant that occurred <five years ( Findings: We identified 748 patients (404 chemotherapy-treated) and 3740 controls. Median age at diagnosis was 19.0 years [interquartile range (IQR): 18.0-21.0] and 29.7 years (IQR: 25.0-37.6) at the end of follow-up. Chemotherapy-treated patients had higher risk than controls for non-TGCT SMN [hazard ratio (HR) = 4.5, 95% CI: 1.8-11.4], hearing loss/aid (HR = 2.7, 95% CI: 1.8-4.2), Interpretation: Chemotherapy-treated CAYA with TGCT are at elevated risks for non-TGCT SMN, hearing loss, and Funding: Foundation grants-Canadian Institutes of Health Research, Ontario Graduate Scholarship-University of Toronto, and Research Training Competition (RESTRACOMP) award-The Hospital for Sick Children.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.